Conduit bets on three of AstraZeneca’s potential first-in-class assets

Looking to strengthen its pipeline, Conduit Pharmaceuticals forged an exclusive licensing agreement with AstraZeneca to acquire multiple assets with first-in-class potential from the latter, including two HK-4 glucokinase activators, codenamed AZD1656 and AZD5658, and a myeloperoxidase inhibitor AZD5904.